

1 September 2016

ASX Code: MXC

## **Collaboration Agreement signed with Epilepsy Action Australia: For future Australian clinical trials with medicinal cannabis**

- The Company has signed a Collaboration Agreement (COA) with Epilepsy Action Australia (EAA)
- Both parties to collaborate on future joint clinical trials using medicinal cannabis for the treatment of severe epilepsy, further enhancing MXC's expertise in this field
- EAA is the leading Australian epilepsy association that provides support services to children and adults with epilepsy
- COA builds upon the recent appointment of global epilepsy expert, Professor Uri Kramer to MXC's Strategic Advisory Board to direct the development of clinical trials in Australia and Europe
- Under the COA, EAA will introduce MXC's CBD products to its members in accordance with their medical requirements

MGC Pharmaceuticals Ltd (ASX: MXC or "the Company"), is pleased to announce that it has signed a strategic Collaboration Agreement (COA) with Epilepsy Action Australia (EAA). The partnership will see EAA and MGC Pharmaceuticals collaborating to improve health outcomes for people suffering from epilepsy and further enhances the Company's management expertise in the field of epilepsy.

Under the COA, EAA will facilitate and coordinate research partnerships, and assist with the selection of study participants and medical doctors for a future clinical trial into the efficacy of medical cannabis as a potential prevention treatment for epilepsy. MGC Pharmaceuticals is to be responsible for the provision of Active Pharmaceutical Ingredient (API) medicinal cannabis materials for the trial and providing industry knowledge and expertise.

Epilepsy Action Australia's key goals are to increase epilepsy awareness and understanding and assist individuals and families who are living with epilepsy. EAA endeavours to undertake research and advocacy into possible treatments that improve health outcomes for people with epilepsy. According to EAA, it is estimated that over 250,000 Australians are living with epilepsy and that 3% of Australians will experience the condition at some point in their life<sup>1</sup>.

The signing of the COA builds upon the July 2016 appointment of global epilepsy expert, Professor Uri Kramer to the Company's Strategic Advisory Board. Professor Kramer is a leading Israeli Paediatric Epilepsy expert and will be responsible for the development of future clinical trial programs in Australia and Europe.

With appropriate government support and the involvement of key stakeholders, the Company is continuing to progress towards the future commencement of clinical trials in Australia and Europe. A key focus of the clinical trials will relate to medical cannabis as a potential treatment of severe epilepsy in children.

Additionally, under the agenda of "Responsible Use of Cannabis", EAA will introduce MXC's products to its members in accordance with their medical requirements. This could include MXC's future API medicinal cannabis products.

---

<sup>1</sup> [Epilepsy Action Australia: Facts and Statistics](#)

**Nativ Segev, Co-founder and Managing Director, MGC Pharmaceuticals commented:**

“The signing of a COA with Epilepsy Action Australia further enhances our expertise and deepens our networks relating to epilepsy. We look forward to working with Epilepsy Action Australia for the future commencement of clinical trials that explore medical cannabis as a potential treatment for epilepsy.”

**Carol Ireland, CEO and Managing Director, Epilepsy Action Australia commented:**

“I have had significant contact with many families in Australia who have children with devastating, medication resistant epilepsy and also adults who have lived for many years with unrelenting seizures that have made it virtually impossible for them to lead a quality life and participate fully in their communities. We are delighted to collaborate on an initiative that offers new hope.”

**-Ends-**

**For further information, please contact:**

**Media Enquiries**

Andrew Ramadge  
Account Director  
Media and Capital Partners  
+61 475 797 471  
[andrew.ramadge@mcpartners.com.au](mailto:andrew.ramadge@mcpartners.com.au)

**MGC Pharmaceuticals Ltd**

Brett Mitchell  
Executive Chairman  
+61 8 9389 2000  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**About MXC**

MGC Pharmaceuticals Ltd (ASX: MXC) is EU based specialist medical cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabidiol (CBD) resin extract to the growing demand in cosmetics and medical markets in Europe, North America and Australasia. The Company is also developing strategic joint ventures in these key value add industries, as demonstrated with MGC Derma CBD cosmetics.

**Epilepsy Action Australia**

Established in 1952, Epilepsy Action Australia undertakes research and advocacy, and delivers innovative, high quality services across Australia to optimise life outcomes for people with epilepsy. The organisation's aims are to increase epilepsy awareness and understanding in the community, and facilitate self-management of epilepsy for people with the condition.